Medical Cannabis Studies

• View All (505)

Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid (2004)

El sistema de receptores cannabinoides tiene el potencial de reducir tanto el da�o celular excitot�xico como oxidativo. Estos mecanismos celulares pueden ser la base del presunto efecto neuroprotector en modelos animales. El THC y otros cannabinoides pueden ser nuevos objetivos terap�uticos para el tratamiento de la esclerosis lateral amiotr�fica (ELA). View study
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury (2001)

Here we show that, after an injury to the brain of a mouse, Arachidonoyl glycerol (2-AG) may have a neuroprotective role in which the cannabinoid system is involved. We found a significant reduction of cerebral edema, better clinical recovery, reduced infarct volume and reduced hippocampal cell death compared to controls. View study
An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse (Documento PDF da�ado)

View study
An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors (2017)

View study
An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies (2017)

This survey seeks to expand the survey previously done by Bergamaschi et al. in 2011 on the safety and side effects of cannabidiol (CBD), as well as updating literature. This paper focuses on clinical studies and the possible interactions of the CBD with other medications. View study
Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome (2016)

This study demonstrates that CBD or cannabidiol helps reduce seizures of childhood epilepsy, and dravets syndrome. View study
Anandamide and 2-arachidonoylglycerol- pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids (2012)

There is evidence suggesting that AEA and 2-AG possess specific pharmacological properties and that they also participate in different forms of synaptic plasticity and in different behavioral functions, such as learning and memory, reward and addiction, antinociception and anxiety. View study
Anandamide Induces Apoptosis in Human Cells via Vanilloid Receptors (2000)

The results of this study indicate that cannabinoid receptors have a protective role against apoptosis induced by endocannabinoid anandamide (AEA) through vanilloid receptors. View study
Anti-inflammatory Potential of CB1-mediated CAMP Elevation in Mast Cells (2005)

This research was based on defining the role of paper for CB1 in mast cells and identifying the signaling pathways that can mediate the suppressive effects of CB1 ligation in mast cell activation. The results show the complexity of the signaling of the co-expressed native cannabinoid receptors and suggest that some anti-inflammatory effects of the CB1 ligands can be attributed to a sustained increase in the anti-inflammatory potential of the elevation mediated by CB1 (cAMP). View study
Anti-Inflammatory Role of Cannabidiol and O-1602 in Cerulein-Induced Acute Pancreatitis in Mice (2012)

The treatment with cannabidiol or O-1602 significantly improved the pathological changes of mice with experimental acute pancreatitis, showing anti-inflammatory effects. View study
Anti-proliferative effects of anandamide in human hepatocellular carcinoma cells (2012)

A study demonstrating that endogenous cannabinoid anandamide AEA inhibits the proliferation of cancer cells and induces cellular apoptosis, suggesting its therapeutic potential in the treatment of patients with human hepatocellular carcinoma. View study
Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy (2011)

Findings that reveal the therapeutic potential of cannabinoids for the treatment of hepatocellular carcinoma, especially in advanced stages. View study